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Thrombin Primes Responsiveness of Selective Chemoattractant Receptors at a
Site Distal to G Protein Activation
Abstract
To define the molecular basis of human chemoattractant receptor regulation, rat basophilic leukemia
RBL-2H3 cells, which are thrombin- responsive, were transfected to stably express epitope-tagged
receptors for C5a, interleukin-8 (IL-8), formylpeptides (e.g. N-formylmethionyl-leucyl- phenylalanine
(fMLP)), and platelet-activating factor (PAF). Here we demonstrate that both thrombin and a synthetic
peptide ligand for the thrombin receptor (sequence SFLLRN) caused phosphorylation and heterologous
desensitization of the receptors for C5a, IL-8, and PAF but not that for formylpeptides as measured by
agonist-stimulated [35S]guanosine 5'-3-O- (thio)triphosphate binding to membranes. Consistent with the
PAF receptor phosphorylation, both thrombin and thrombin receptor peptide inhibited phosphoinositide
hydrolysis, Ca2+ mobilization, and degranulation stimulated by PAF. Unexpectedly, despite heterologous
desensitization at the level of receptor/G protein activation, there was enhancement ('priming') by
thrombin of subsequent activities stimulated by C5a and IL-8 as well as fMLP. The priming effect of
thrombin was blocked by its inhibitor, hirudin. However, two other activators of the thrombin receptor, the
peptide SFLLRN and trypsin, stimulated Ca2+ mobilization in RBL-2H3 cells but did not cause priming. In
addition, SFLLRN and the thrombin receptor antagonist peptide FLLRN both inhibited thrombin-induced
Ca2+ mobilization but not priming. Furthermore, the proteolytically active γ-thrombin, which does not
stimulate the tethered ligand thrombin receptor and caused little or no Ca2+ mobilization in RBL-2H3 cells,
effectively primed the response to fMLP. These data demonstrate that heterologous receptor
phosphorylation and attenuation of G protein activation are not, by themselves, sufficient for the inhibition
of biological responses mediated by C5a and IL-8. Moreover, thrombin appears to utilize mechanism(s)
independent of its tethered ligand receptor to selectively prime phospholipase C-mediated biological
responses of the C5a, IL-8, and formylpeptide receptors but not PAF. Because C5a, IL- 8, and
formylpeptide activate phospholipase Cβ2, whereas PAF stimulates a different phospholipase C, the
striking selectivity of thrombin's priming may be mediated via its ability to enhance receptor-mediated
activation of phospholipase Cβ2.
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To define the molecular basis of human chemoattractant receptor regulation, rat basophilic leukemia RBL2H3 cells, which are thrombin-responsive, were transfected to stably express epitope-tagged receptors for
C5a, interleukin-8 (IL-8), formylpeptides (e.g. N-formylmethionyl-leucyl-phenylalanine (fMLP)), and plateletactivating factor (PAF). Here we demonstrate that both
thrombin and a synthetic peptide ligand for the thrombin receptor (sequence SFLLRN) caused phosphorylation and heterologous desensitization of the receptors
for C5a, IL-8, and PAF but not that for formylpeptides as
measured by agonist-stimulated [35S]guanosine 5*-3-O(thio)triphosphate binding to membranes. Consistent
with the PAF receptor phosphorylation, both thrombin
and thrombin receptor peptide inhibited phosphoinositide hydrolysis, Ca21 mobilization, and degranulation
stimulated by PAF. Unexpectedly, despite heterologous
desensitization at the level of receptor/G protein activation, there was enhancement (“priming”) by thrombin of
subsequent activities stimulated by C5a and IL-8 as well
as fMLP. The priming effect of thrombin was blocked by
its inhibitor, hirudin. However, two other activators of
the thrombin receptor, the peptide SFLLRN and trypsin, stimulated Ca21 mobilization in RBL-2H3 cells but
did not cause priming. In addition, SFLLRN and the
thrombin receptor antagonist peptide FLLRN both inhibited thrombin-induced Ca21 mobilization but not
priming. Furthermore, the proteolytically active
g-thrombin, which does not stimulate the tethered ligand thrombin receptor and caused little or no Ca21
mobilization in RBL-2H3 cells, effectively primed the
response to fMLP. These data demonstrate that heterologous receptor phosphorylation and attenuation of G
protein activation are not, by themselves, sufficient for
the inhibition of biological responses mediated by C5a
and IL-8. Moreover, thrombin appears to utilize mechanism(s) independent of its tethered ligand receptor to
selectively prime phospholipase C-mediated biological
responses of the C5a, IL-8, and formylpeptide receptors
but not PAF. Because C5a, IL-8, and formylpeptide activate phospholipase Cb2, whereas PAF stimulates a different phospholipase C, the striking selectivity of
thrombin’s priming may be mediated via its ability to
enhance receptor-mediated activation of phospholipase
Cb2.
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Phagocytic leukocytes respond to multiple inflammatory signals and play a key role in immunological reactions. Among the
well defined stimulants for leukocytes are chemoattractants: a
cleavage product of the fifth component of complement (C5a),
interleukin-8 (IL-8),1 platelet-activating factor (PAF), and Nformylated peptides (e.g. fMLP) (1–3). These chemoattractants
mediate their biological responses via the activation of cell
surface receptors that are coupled to phospholipase C via G
proteins. Leukocyte responsiveness to chemoattractants can be
“primed” or desensitized by prior stimulation (1, 4, 5). Priming
or enhanced responsiveness to subsequent stimuli may be
caused by low concentrations of substance P, chemoattractants,
phorbol esters, Ca21 ionophores, and cytokines, including granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-a (1, 6, 7). The molecular mechanism by which
these agents prime responses in leukocytes have not yet been
determined. Desensitization of cellular responses to a stimulus
can either be homologous or heterologous (8). The former is
specific for a given ligand/receptor, whereas the latter involves
multiple ligands/receptors. There is convincing evidence that
receptor phosphorylation is one mechanism by which many G
protein-coupled receptors undergo both homologous and heterologous desensitization. Recent evidence indicates an additional mechanism for chemoattractant receptor desensitization, a process resulting in reduced phosphoinositide hydrolysis
via a decreased activity of phospholipase C (9).
Thrombin, a serine protease generated at sites of vascular
injury, is a key enzyme in the coagulation cascade but may also
be important in regulating inflammatory and proliferative responses (10, 11). Thrombin activates a variety of cells including
platelets, leukocytes, fibroblasts, and endothelial cells at least
in part via its interaction with cell surface receptors (12–15).
One such receptor is a member of the seven transmembrane
domain receptor superfamily whose activation proceeds via a
novel mechanism (16). Thrombin binds to and cleaves its receptor’s extracellular amino-terminal extension, thereby unmasking an amino-terminal peptide, whose binding site resides
in the first six amino acids (sequence SFLLRN) (16, 17). This
tethered ligand binds to the thrombin receptor and induces its
activation. Thrombin also binds to the platelet membrane glycoprotein Ib (GPIb) to activate Ca21 mobilization and platelet
aggregation (18, 19). However, thrombin-induced chemotaxis
in monocytes and growth factor-like effect in fibroblasts appear
to be mediated via the activation of as yet undefined thrombin
receptors (14, 20, 21).
1
The abbreviations used are: IL-8, interleukin-8; fMLP, N-formylmethionyl-leucyl-phenylanaline; PAF, 1-O-alkyl-2-acetyl-sn-glycero-3phosphocholine; ET-FR, ET-C5aR, ET-IL-8R, and ET-PAFR, epitopetagged receptors for fMLP, C5a, IL-8, and PAF, respectively; PMA,
phorbol 12-myristate 13-acetate; TRP, thrombin receptor peptide; PIP2,
phosphatidylinositol 4,5-bisphosphate; GTPgS, guanosine 59-3-O-(thio)
triphosphate; GPIb, glycoprotein Ib; Ptx, pertussis toxin; PLC,
phospholipase C.
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FIG. 1. Phosphorylation of stably expressed chemoattractant receptors. 32P-Labeled RBL-2H3 cells expressing ET-FR (A), ET-C5aR (B),
ET-IL-8R (C), or ET-PAFR (D) were left unstimulated (lanes 1) or stimulated with their respective ligands (lanes 2) fMLP (1 mM), C5a (100 nM),
IL-8 (100 nM), and PAF (100 nM), with PMA (100 nM) (lanes 3), with thrombin (1 unit/ml) (lanes 4), or with TRP (100 mM) (lanes 5). The reactions
were stopped 3 min after stimulation by adding excess ice-cold phosphate-buffered saline. The samples were washed, lysed, and immunoprecipitated with 12CA5 antibody. The proteins were resolved on a 10% SDS-polyacrylamide gel electrophoresis and visualized by autoradiography. The
data shown are from one of three similar experiments.

To better define the molecular basis of chemoattractant receptor regulation, we used thrombin-responsive rat basophilic
leukemia RBL-2H3 cells to stably express epitope-tagged receptors for chemoattractants formylpeptide, C5a, IL-8, and
PAF (4, 5, 9). Using RBL-2H3 cells expressing fMLP and C5a
receptors, we previously showed that thrombin causes phosphorylation and heterologous desensitization of the C5a but not
formylpeptide receptor at the level of receptor-mediated G protein activation (4). The present study was undertaken to more
precisely define the effects of thrombin on responses stimulated
by fMLP, C5a, and other chemoattractant receptors. Here we
describe a novel finding that thrombin, utilizing a mechanism
unrelated to the activation of its tethered ligand G protein
coupled receptor, selectively primes phosphoinositide hydrolysis, Ca21 mobilization, and exocytosis stimulated via the activation of receptors for formylpeptide, C5a, and IL-8 but not
PAF.
EXPERIMENTAL PROCEDURES

Materials—[32P]Orthophosphate (8500 –9120 Ci/mmol), myo-[23
H(N)]-inositol (24.4 Ci/mmol), and [35S]GTPgS (1300Ci/mmol) were
purchased from DuPont NEN. Monoclonal 12CA5 antibody was obtained from Berkeley Antibody Co. Earle’s modified Eagle’s medium
and all tissue culture reagents were purchased from Life Technologies,
Inc. Indo-1 acetoxymethyl ester and pluronic acid were purchased from
Molecular Probes. C5a, fMLP, PAF, trypsin (Type I), a-chymotrypsin
(Type VII; 1-chloro-3-tosylamido-7-amino-2-heptanone-treated), and
hirudin were obtained from Sigma. Cathepsin G and elastase were from
Athens Research and Technology Inc. IL-8 was purchased from Genzyme. Human a-thrombin (specific activity, 1052 NIH units/mg) was
obtained from Calbiochem. Human a-thrombin (specific activity, 2680
units/mg), g-thrombin (specific activity, 1.71 units/mg), and diisopropylphosphofluoridate-inactivated a-thrombin (specific activity, 0.078 unit/
mg) were generous gifts from Dr. J. W. Fenton II (New York Department of Health, Albany, NY). The thrombin receptor agonist peptide (SFLLRN) was purchased from Peninsula Laboratories, and the
antagonist peptide FLLRN was synthesized by Quality Controlled
Biochemicals Inc.
Phosphorylation of Epitope-tagged Chemoattractant Receptors Stably
Expressed in RBL-2H3 Cells—Phosphorylation of receptors was carried
out exactly as described (4). Briefly, RBL-2H3 cells (2.0 3 106) expressing chemoattractant receptors were seeded in 60-mm tissue culture
dishes in normal growth medium and cultured overnight at 37 °C. The
following day each dish was washed twice with 5 ml of phosphate-free
Dulbecco’s modified Eagle’s medium and incubated with 150 mCi of
[32P]orthophosphate for 90 min. Adherent cells were stimulated with
the indicated stimulants, and the phosphorylated receptors were immunoprecipitated with 12CA5 antibody, analyzed by SDS-polyacrylamide gel electrophoresis, and visualized by autoradiography.
[35S]GTPgS Binding—RBL-2H3 cells expressing the appropriate
chemoattractant receptors were treated with the indicated stimulants
for 3 min at 37 °C, and membranes were prepared as described (4).
[35S]GTPgS binding to 10 mg of membranes was performed as described
previously (22).
Calcium Measurements—RBL-2H3 cells (3 3 106) were loaded with 1

mM indo-1 acetoxymethyl ester in the presence of 1 mM pluronic acid for
30 min at room temperature. The cells were then washed and resuspended in 1.5 ml of buffer. Calcium measurements were carried out in
a Perkin Elmer fluorescence spectrophotometer (Model 650 –19) with an
excitation wavelength of 355 nm and an emission wavelength of 410
nm. Maximum and minimum fluorescence were determined in the
presence of 0.1% Triton-X and 20 mM Tris-HCl, pH. 8.0, 5 mM EGTA,
respectively. Intracellular calcium concentrations were calculated using the following formula: [Ca21]i 5 Kd (F 2 Fmin/Fmax 2 F) (23).
Assay of [3H]Inositol Products and b-Hexosaminidase—RBL-2H3
cells (0.5 3 104/well) were seeded in a 96-well tissue culture plate and
cultured overnight with 2 mCi/ml [3H]inositol in inositol-free medium
supplemented with 10% dialyzed fetal bovine serum. Cells were washed
with HEPES-buffered saline supplemented with 20 mM LiCl2 in the
presence of 0.1% bovine serum albumin and preincubated with 50 ml of
the same buffer in the absence and the presence of thrombin or TRP.
Cells were then stimulated with the desired ligand, and the reaction
was terminated 10 min later by placing the plate on ice. Supernatant or
cell lysate (10 ml) was removed, and release of b-hexosaminidase was
determined as described (4, 5). [3H]Inositol phosphates were extracted
from the same wells by the addition of 200 ml of chloroform:methanol:4
N HCl (100:200:2), 75 ml of 0.1 N HCl, and 75 ml of chloroform. Total
[3H]inositol phosphates were separated on columns of Dowex formate (4).
For the assay of [3H]phosphatidylinositol 4,5-bisphosphate
([3H]PIP2), RBL-2H3 cells (0.5 3 105) were labeled overnight with
[3H]inositol (10 mCi/ml). The lipids were extracted and separated by
chromatography on silica gel 60 F254 that had been treated with a
solution of 2 mM EDTA and 1% potassium oxalate as described (24).
Unlabeled PIP2 (20 mg) were added to all extracts, which were then
evaporated to dryness under nitrogen. The residues were dissolved in
chloroform:methanol (2:1), and mixture was applied to the plates. The
chromatographs were developed with the following solvent system:
chloroform:methanol:4 N NH4OH (9:7:2, v/v/v). The plates were exposed
to iodine vapor to visualize the PIP2. The spots were scraped from the
plate, and the amount of [3H]PIP2 was determined by scintillation
counting.
RESULTS

Phosphorylation and Desensitization of Human Chemoattractant Receptors—RBL-2H3 cells stably expressing epitopetagged receptors for fMLP (ET-FR), C5a (ET-C5aR), IL-8
(ET-IL-8R), and PAF (ET-PAFR) were incubated with [32P]
orthophospate and stimulated with their respective ligands,
phorbol 12-myristate 13-acetate (PMA), thrombin (1 unit/ml),
or TRP (sequence SFLLRN, 100 mM). All receptors underwent
homologous phosphorylation (Fig. 1). PMA, thrombin, and TRP
caused phosphorylation of ET-C5aR, ET-IL-8R, and ET-PAFR
but not ET-FR. The extent of thrombin- and TRP-induced phosphorylation of the susceptible receptors was less than agonistinduced receptor phosphorylation. To determine whether receptor phosphorylation was correlated with desensitization at
the level of G protein activation, cells expressing selected receptors (ET-C5aR and ET-PAFR) were treated with their respective ligands (C5a or PAF), PMA, thrombin, or TRP, and
agonist-stimulated [35S]GTPgS binding to membranes was de-
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FIG. 3. Effects of thrombin and TRP on Ca21 mobilization stimulated by fMLP, C5a, IL-8, and PAF. RBL-2H3 cells expressing
ET-FR, ET-C5aR, ET-IL-8R, and ET-PAFR were loaded with indo-1
and were left untreated (Control) or stimulated with thrombin (1 unit/
ml) or TRP (100 mM) and 3 min later rechallenged with submaximal
concentrations of fMLP, (10 nM), C5a (1 nM), IL-8 (3 nM), or PAF (0.2
nM), and chemoattractant-stimulated Ca21 mobilization was determined. The values presented are the peak Ca21 mobilization stimulated
by chemoattractants after the basal (;150 nM) has been subtracted.
The data are the means 6 S.E. of three experiments.

FIG. 2. Effects of thrombin and TRP on chemoattractant receptor-stimulated [35S]GTPgS binding to membranes. RBL-2H3
cells expressing ET-C5aR and ET-PAFR were left untreated (CON) or
treated with their respective ligands C5a or PAF, PMA, thrombin
(THR), or TRP as in Fig. 1. Membranes were prepared and assayed for
agonist-stimulated [35S]GTPgS. The values are presented as percentages of net [35S]GTPgS bound, which is defined as the maximum
amount of agonist-stimulated response from untreated membranes. For
ET-C5aR the basal and C5a-stimulated responses (untreated) were
7097 6 216 and 15472 6 47 cpm, respectively. For ET-PAFR, the basal
and PAF-stimulated (untreated) responses were 6446 6 350 and 12330
6 48 cpm, respectively. The basal [35S]GTPgS bound to membranes
treated with ligand, PMA, thrombin, and TRP were similar to basal
responses in the absence of pretreatment. The data are the means 6
S.E. of three experiments performed in triplicate.

termined. As shown in Fig. 2, thrombin, TRP, and PMA inhibited the responses to C5a and PAF. Similar to receptor phosphorylation, the extent of heterologous desensitization was less
than homologous desensitization for both receptors (Fig. 2).
Thrombin did not cause inhibition of fMLP-stimulated
[35S]GTPgS binding to membranes (4).
Effects of Thrombin and TRP on Ca21 Mobilization in Response to Chemoattractants in RBL-2H3 Cells—Thrombin (1
unit/ml) and TRP (100 mM) caused a rapid and transient increase in intracellular Ca21 concentration, which reached a
maximum of 1074 6 60 and 814 6 25 nM respectively, 5–10 s
after stimulation and returned to basal within 2–3 min. These
responses were due to the mobilization of intracellular Ca21
because chelation of extracellular Ca21 with EGTA had no
significant effect on thrombin- or TRP-induced response (data
not shown). Exposure of cells to thrombin followed 3 min later
by a submaximal concentration of fMLP (10 nM) resulted in a
4-fold enhancement of Ca21 mobilization when compared with
the response in the absence of thrombin (Fig. 3). TRP, however,
had no effect on the Ca21 response stimulated by fMLP. Pertussis toxin (Ptx, 100 ng/ml, 4 h) had no effect on Ca21 mobilization stimulated by thrombin but totally blocked the response to fMLP both in thrombin-treated and untreated cells

(data not shown). The effects of thrombin and TRP were also
tested on Ca21 mobilization stimulated by C5a, IL-8, and PAF
in cells expressing appropriate receptors. As shown in Fig. 3,
thrombin but not TRP-primed Ca21 mobilization stimulated by
the C5a and IL-8 by 2–3-fold. In contrast, both thrombin and
TRP inhibited PAF-stimulated Ca21 mobilization. To further
test the specificity of thrombin for priming, its effect on Ca21
mobilization stimulated by cross-linking by antigen of endogenously expressed cell surface IgE receptors (24) was determined. Antigen (dinitrophenylated bovine serum albumin; 1
ng/ml) alone stimulated a 152 6 14 nM mobilization of Ca21,
whereas pretreatment with thrombin (1 unit/ml, 3 min) followed by antigen resulted in a 128 6 12 nM mobilization of
Ca21.
Effects of Thrombin and TRP on Chemoattractant Receptorstimulated Phosphoinositide Hydrolysis and Secretion of
b-Hexosaminidase—In the absence of thrombin or TRP, fMLP
caused a dose-dependent increase in the generation of [3H]inositol phosphates and release of b-hexosaminidase (Fig. 4).
Thrombin enhanced the maximum responses stimulated by
fMLP by 2–3-fold. TRP (100 mM), however, had no effect on
fMLP-induced responses. The dose-response effect of thrombin
on fMLP-stimulated phosphoinositide hydrolysis demonstrated
that the EC50 and EC100 values for priming by thrombin were
approximately 0.1 and 1.0 unit/ml, respectively (data not
shown).
The effects of thrombin and TRP on the generation of [3H]inositol phosphates and secretion of b-hexosaminidase stimulated by C5a, IL-8, and PAF were also determined. Cells were
preincubated with thrombin (1 unit/ml) or TRP (100 mM) for 3
min and then stimulated with concentrations of chemoattractants that alone caused a 2–3-fold increase in the generation of
[3H]inositol phosphates and release of about 20 –30% of total
cellular b-hexosaminidase. As shown in Fig. 5, thrombin but
not TRP primed both phosphoinositide hydrolysis and secretion
stimulated by C5a and IL-8. In contrast, both thrombin and
TRP inhibited these responses to PAF.
The fMLP-induced generation of [3H]inositol phosphates was
used to further characterize the priming phenomenon. The
priming effect of thrombin was not dependent on its continuous
presence because replacement of thrombin-containing buffer 3
min after its addition with fresh buffer without thrombin resulted in the same magnitude of priming as when thrombin
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FIG. 4. Effects of thrombin and TRP on dose-response of fMLPstimulated generation of [3H]inositol phosphates and release of
b-hexosaminidase. [3H]Inositol-labeled RBL-2H3 cells expressing
ET-FR were left untreated (control) or treated with thrombin (1 unit/
ml) or TRP (100 mM) for 3 min in the presence of LiCl (20 mM) and
stimulated with different concentrations of fMLP. The reactions were
quenched 10 min after stimulation. The generation of total [3H]inositol
phosphates (A) and release of b-hexosaminidase (B) were determined as
described under “Experimental Procedures.” The basal responses for A
(300 6 14, 800 6 3, and 450 6 20 cpm) and for B (2.3 6 0.1, 4.8 6 0.5,
and 3.5 6 0.3%) in the presence of buffer, thrombin, and TRP, respectively, were subtracted from the values shown. The data shown are the
means 6 S.E. of one of four experiments performed in triplicate.

was not removed by washing (Fig. 6A). The priming effect of
thrombin reached a maximum by 3–5 min, remained elevated
for about 15 min, and returned to basal by 60 min (Fig. 6B).
When cells were preincubated for 5 min with thrombin in the
presence of Ca21 (1 mM) or EGTA (100 mM; no added Ca21),
washed, and stimulated with fMLP in the presence of Ca21 (1
mM), the extent of priming was the same (data not shown).
To test whether the effect of thrombin correlated with an
increase in substrate availability for phospholipase C, RBL-H3
cells were labeled with [3H]inositol and exposed to thrombin (1
unit/ml) or TRP (100 mM) for 5 min and then the amount of
[3H]PIP2 was determined. The levels of incorporation of [3H]inositol in to PIP2 in response to buffer, thrombin, and TRP
were 4309 6 95, 4329 6 210, and 4286 6 105, respectively.
Specificity of Thrombin-mediated Responses in RBL-2H3
Cells—Thrombin receptor agonist and antagonist peptides
SFLLRN and FLLRN (16) were utilized to test the role of the
tethered ligand thrombin receptor on priming. As shown in
Table I, the peptide SFLLRN stimulated a substantial Ca21
mobilization and desensitized the thrombin-stimulated Ca21
response by .70% but did not inhibit the priming effect of
thrombin. The thrombin receptor antagonist peptide FLLRN
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FIG. 5. Effects of thrombin and TRP on C5a-, IL-8-, and PAFmediated generation of [3H]inositol phosphates and release of
b-hexosaminidase in RBL-2H3 cells. [3H]Inositol-labeled RBL-2H3
cells expressing ET-C5aR, ET-IL-8R, or ET-PAFR were left untreated
(control) or were treated with thrombin (1 unit/ml) or TRP (100 mM) for
3 min in the presence of LiCl (20 mM) and stimulated with C5a (10 nM),
IL-8 (100 nM), or PAF (0.3 nM). The reactions were quenched 10 min
after stimulation. The generation of total [3H]inositol phosphates (A)
and release of b-hexosaminidase (B) were determined from the same
samples. The basal responses were similar to those in Fig. 4 and were
subtracted from the values shown. The data are the means 6 S.E. of one
of three experiments performed in triplicate.

caused no Ca21 mobilization and inhibited the response to
thrombin by . 75% but did not block priming by thrombin
(Table I).
Hirudin binds to the anion binding exosite and the enzymatic
cleavage pocket of thrombin and prevents thrombin from binding and cleaving its receptor (25). Hirudin completely blocked
both Ca21 mobilization and priming of the fMLP response by
thrombin but had no effect on the fMLP response itself
(Table II). Thrombin inactivated by diisopropylphosphofluoridate has no catalytic activity but still binds to the seven
transmembrane domain thrombin receptor via the anion
binding exosite (26). Diisopropylphosphofluoridate-inactivated
a-thrombin did not stimulate Ca21 mobilization in RBL-2H3
cells and had no effect on the fMLP response (Table II).
g-Thrombin retains its catalytic activity, but its binding site for
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FIG. 6. Characteristics of thrombin-induced priming. A, [3H]inositol-labeled RBL-2H3 cells expressing ET-FR were treated with buffer or
thrombin (1 unit/ml for 3 min) containing LiCl (20 mM) and stimulated with fMLP (1 mM) in the continuous presence of thrombin (1). Alternatively,
cells were preincubated with thrombin, washed, and exposed to a fresh medium without thrombin but containing LiCl (20 mM) and stimulated with
fMLP (2). B, cells were exposed to thrombin for different time periods in the absence of LiCl, washed, and exposed to fMLP in a buffer containing
LiCl. The reactions were quenched 10 min after the addition of fMLP and generation of total [3H]inositol phosphates were determined. The data
shown are the means 6 S.E. of one of four experiments performed in triplicate.
TABLE I
Effects of thrombin receptor peptides on the priming of
fMLP-induced Ca21 mobilization
Indo-1-loaded RBL-2H3 cells expressing ET-FR were preincubated
with buffer (control), peptides SFLLRN (100 mM), or FLLRN (100 mM)
for 3 min and then stimulated with thrombin (0.2 unit/ml) followed by
fMLP (10 nM), and peak intracellular Ca21 mobilization was determined after each stimulation. The basal Ca21 concentrations in the
absence of stimulation were 155 6 4, n 5 18 and were subtracted from
the values shown. The data are the means 6 S.E. of three experiments.
Intracellular Ca21 concentration
Treatment
Peptides

Thrombin

fMLP

nM

Control
Thrombin
SFLLRN, thrombin
FLLRN, thrombin

680 6 60
060

454 6 50
128 6 5.7
120 6 10.9

173 6 19
447 6 47
465 6 35
483 6 14

the tethered ligand thrombin receptor is disrupted (26).
g-Thrombin itself caused only a small increase in Ca21 mobilization but primed the response to fMLP by about 3-fold.
Trypsin, a serine protease, stimulated a substantial mobilization of intracellular Ca21 in RBL-2H3 cells but did not prime
the response to fMLP. Another serine protease, elastase, which
did not stimulate Ca21 mobilization, had no effect on the fMLP
response (Table II). Other proteases, such as chymotrypsin and
cathepsin G stimulated little or no Ca21 mobilization but
primed the response to fMLP by approximately 1.5-fold. This
compares with a 4-fold priming of the fMLP response by
thrombin.
DISCUSSION

Regulation of receptor action has been the subject of intense
investigation with one focus being the mechanisms of desensitization. There is abundant evidence for a role of receptor
phosphorylation in homologous and heterologous desensitization (8). Indeed, the inability of the formylpeptide receptor to
undergo heterologous desensitization was attributed to the absence of a phosphorylation site for protein kinase C on any of its
predicted intracellular loops (4, 27). The data presented herein
demonstrate that both thrombin and TRP stimulated phospho-

TABLE II
Effects of proteases on fMLP-induced Ca21 mobilization
Indo-1-loaded RBL-2H3 cells expressing ET-FR were preincubated
with buffer (control), thrombin (1 unit/ml), a mixture of hirudin (2
units/ml) and thrombin (1 unit/ml), diisopropylphosphofluoridate-inactivated a-thrombin (3 mg/ml), g-thrombin (1 mg/ml), trypsin (25 mg/ml),
chymotrypsin (25 mg/ml), cathepsin G (10 mg/ml), and elastase (20
mg/ml) and 3 min later stimulated with fMLP (10 nM), and peak intracellular Ca21 mobilization was determined after each stimulation. The
basal Ca21 concentrations in the absence of stimulation was 155 6 4, n
5 18 and were subtracted from the values shown. The data are the
means 6 S.E. of three experiments. Significant enhancement of responses from untreated cells are indicated by an asterisk for p , 0.05
and two asterisks for p , 0.01.
Intracellular Ca21 concentration
Treatment
First dose

Second dose
(fMLP)

1074 6 60
060
060
47 6 14
695 6 18
060
060
23 6 1.4

161 6 5.2
643 6 17**
167 6 5.5
158 6 13
440 6 27**
175 6 7
159 6 2
272 6 26*
264 6 34*

Fold priming

nM

Control
Thrombin
Hirudin 1 thrombin
DIP a-thrombin
g-Thrombin
Trypsin
Elastase
Chymotrypsin
Cathepsin G

4.0
0
0
2.5
0
0
1.7
1.6

rylation of the chemoattractant receptors for C5a, IL-8, and
PAF but not for fMLP. Furthermore, phosphorylation of susceptible receptors was correlated with heterologous desensitization at the level of receptor/G protein coupling. Unexpectedly, although both thrombin and TRP decreased G protein
activation by C5a, thrombin primed subsequent phosphoinositide hydrolysis, Ca21 mobilization, and degranulation stimulated by all the peptide chemoattractants (fMLP, C5a, and
IL-8). The specificity of thrombin for the priming of peptide
chemoattractant-mediated responses is demonstrated by the
finding that thrombin inhibited these responses to PAF and
had no effect on Ca21 mobilization stimulated by the IgE receptors. These data suggest a surprising complexity in the
regulation of receptor actions. Whereas signals can lead to
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receptor phosphorylation and desensitization at an early stage
in the peptide chemoattractant signal transduction pathway,
the same or other signals may result in markedly enhanced
downstream activities.
The data herein indicate that the priming effect of thrombin
requires its proteolytic activity but is unlikely to be mediated
via its tethered ligand receptor. This contention is based on the
following observations. The peptide agonist of the thrombin
receptor, SFLLRN, stimulated Ca21 mobilization in RBL-2H3
cells but did not prime the response to fMLP. Desensitization of
the thrombin receptor by SFLLRN and treatment with the
thrombin receptor antagonist peptide FLLRN both inhibited
thrombin-induced Ca21 mobilization by .70%, but neither
blocked thrombin’s ability to prime Ca21 mobilization to fMLP.
g-Thrombin, which does not bind to the tethered ligand thrombin receptor but has proteolytic activity (26), stimulated little
or no Ca21 mobilization but effectively primed the response to
fMLP. The priming signal is also unlikely to be derived from
peptide chemoattractant receptors, because they desensitize
each other’s inositol 1,4,5-trisphosphate formation and Ca21
mobilization (9). The effect of thrombin is not solely due to its
serine protease activity because trypsin and elastase, which
are serine proteases (28), did not cause priming. However,
other proteases such as cathepsin G and chymotrypsin primed
fMLP-stimulated Ca21 mobilization, albeit to a lesser extent
than thrombin. Whether cathepsin G and chymotrypsin utilize
the same or different mechanisms to cause priming remains to
be determined.
In fibroblasts, both thrombin and TRP stimulate a transient
Ca21 mobilization of similar magnitude, but only thrombin is
mitogenic (14). The mitogenic signal of thrombin persist long
after (30 min) the transient Ca21 mobilization has returned to
basal (29). Based on these observations, the existence of an
additional receptor for thrombin’s mitogenic activity has been
postulated (14, 29). The identity of this putative receptor or
mechanism is yet to be determined. The data herein showing
that both thrombin and TRP stimulate transient Ca21 mobilization but only thrombin provides a sustained priming signal
suggest that the priming and mitogenic responses of thrombin
may be mediated via a similar pathway. In platelets, two glycoproteins (GPIb and GPV) interact with thrombin, but the
biological significance of these interactions is not known (18,
19, 30 –32). GPIb is a high affinity thrombin receptor in human
platelets (18, 19). The demonstration that g-thrombin, which
does not bind to GPIb in human platelets (33), causes priming
in RBL-2H3 cells suggests that GPIb is unlikely to be involved
in priming. GPV (molecular mass, 82 kDa) is the only detectable membrane surface protein to be hydrolyzed by both a- and
g-thrombin as well as by chymotrypsin (30 –32). Its proteolysis
results in the generation and extracellular release of a 69.5kDa soluble fragment. If GPV is expressed in RBL-2H3 cells, it
is a candidate for involvement in priming.
The phenomenology of priming of chemoattractant receptormediated responses have been well delineated, but the molecular mechanisms are not known. For example, granulocytemacrophage colony-stimulating factor enhances Ca21
mobilization and superoxide generation stimulated by both
peptide (fMLP and C5a) and lipid (PAF) chemoattractants as
well as by direct activation of G proteins (6). It has been
proposed that the priming effect of granulocyte-macrophage
colony-stimulating factor may reside in its ability to cause de
novo synthesis of cellular G proteins or activation of phosphoinositide kinase, which increases the availability of substrates
for phospholipase C (7, 34). In the studies presented here, the
effect reached a maximum 3–5 min after thrombin addition,
and thus de novo protein synthesis is unlikely to be involved. In
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addition, thrombin actually decreased G protein activation by
the C5a receptor yet primed its subsequent responses. Furthermore, under optimal conditions of priming, thrombin had no
significant effect on PIP2 levels in RBL-2H3 cells. The striking
selectivity of thrombin for priming responses for peptide chemoattractants (fMLP, C5a, and IL-8) indicates that the target
is distal to the receptor but is a component of the signal transduction pathway shared by fMLP, C5a, and IL-8 but not PAF.
The peptide chemoattractant receptors couple to a Ptx-sensitive G protein, presumably Gia2, whereas PAF receptors utilize a predominantly Ptx-insensitive G protein (3, 35). Cotransfection studies in COS cells demonstrated that fMLP, C5a, and
IL-8 utilize bg subunit (Gbg) of Gia2 to activate PLCb2,
whereas PAF utilizes the a subunit of a Gq-like G protein to
activate a different PLC (2, 36, 37). The finding that Ptx blocks
fMLP-induced Ca21 mobilization in both thrombin-treated and
untreated cells indicates that priming is not simply a switch in
the coupling of the fMLP receptor from a Ptx-sensitive to a
Ptx-insensitive G protein.
The activity of PLC is a likely locus for the priming event
because phosphoinositide hydrolysis stimulated by peptide chemoattractants is enhanced, although the enzyme’s substrate
level is not. How thrombin primes chemoattractant receptormediated phospholipase C activation can only be speculated at
present. Thrombin primes responses to chemoattractant receptors that utilize Gbg to activate PLC, so modification of either
Gbg or PLC by thrombin may lead to enhanced generation of
inositol phosphates. The g subunits of heterotrimeric G proteins (Gg) are members of a family of proteins that are posttranslationally modified at their carboxyl termini by isoprenylation, proteolytic cleavage, and carboxymethylation (38). This
modification of Gg is essential for membrane association of Gbg
and activation of effector molecules such as PLCb2 (39). Indeed, demethylation of Gbg, which does not affect receptormediated GTPgS binding to G proteins, is at least 10-fold less
effective in stimulating PLCb2 than its methylated counterpart (40). Moreover, fMLP-stimulated carboxymethylation of
Gg2 is associated with neutrophil activation (41, 42). It is
therefore possible that thrombin enhances the carboxymethylation levels of Gg2, resulting in more efficient stimulation of
PLCb2. This would explain the observation that thrombin enhances PLC-mediated respones to peptide chemoattractant receptors despite the fact that thrombin partially inhibits their G
protein activation, as measured by GTPgS binding to
membranes.
In human platelets, thrombin causes proteolytic cleavage of
the 155-kDa PLCb3 in a calpain-dependent manner to generate a 100-kDa fragment (43). The demonstration that this and
a 110-kDa truncated form of the enzyme display markedly
enhanced stimulation by Gbg when compared with the native
PLCb3 (43, 44) suggests that priming by thrombin could involve proteolytic cleavage of PLCb. In addition, a synthetic
peptide corresponding to amino acids 448 – 464 of PLCb2 stimulates the activity of this enzyme (45). It has been suggested
that the peptide does not stimulate PLCb2 activity per se but
enhances the ability of an already active enzyme to hydrolyze
additional substrates. It has not been determined whether
thrombin leads to the formation of such a peptide in RBL-2H3
cells. There is evidence that PLCg possesses a domain within
its structure that inhibits the catalytic activity of the enzyme
(46). Thus, processes that enhance the ability of PLC to be
activated may do so via the release of an inhibitory constraint.
Therefore, the ability of thrombin to modify the Gbg, cause
proteolytic cleavage of PLCb2, remove an inhibitory constraint
from the enzyme or enhance its activation by other mechanisms could explain the observed specificity for thrombin-in-
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duced priming. These possibilities are amenable to future
investigations.
The data herein demonstrate that thrombin modifies RBL2H3 cells to selectively enhance the phospholipase C-mediated
responses to peptide chemoattractants (fMLP, C5a, and IL-8).
We speculate that the striking selectivity of thrombin for priming peptide chemoattractant receptor-mediated responses is
due to its ability to enhance the ligand-stimulated activation of
PLCb2. Of note, we have recently characterized a new form of
cross-desensitization among receptors for peptide chemoattractants and suggested that the mechanism of this type of regulation involves inhibition of PLCb2 activity (9, 47). Thus, modulation of the activity of phospholipases could have a major
regulatory role in cross-receptor signaling. Understanding the
molecular details of how differential regulation of PLCb2 activity results in the priming and cross-desensitization of peptide chemoattractant receptors should provide new and important information on the mechanisms controlling receptor
regulation.
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